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Background
Myocardial replacement fibrosis detected as late gadoli-
nium enhancement (LGE) on cardiac magnetic reso-
nance imaging (CMR) and elevated serum cardiac
troponin T levels measured with highly sensitive assays
(hs-cTnT) have separately been shown to be associated
with subsequent heart failure events in patients with
non-ischemic cardiomyopathy (NICMP). Correlations
between the two markers have also been reported, but
limited data exist on the significance of elevated hs-
cTnT levels and LGE presence in conjunction on heart
failure events. We examined the association of these
markers with heart failure outcomes in NICMP patients
presenting to a tertiary center
Methods
Patients who presented for CMR between April 2008 and
January 2012, received intravenous gadolinium, con-
sented for blood draw, and were diagnosed with NICMP
were included. Patients were excluded for any evidence
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Table 1 Baseline characteristics, cardiac parameters derived from magnetic resonance imaging, and serum troponin
levels.
Variable* Fibrosis Absent (n = 39) Fibrosis Present (n = 35)
Age (years) 58 (44, 68) 58 (45, 70)
Male (%) 61.5 60.0





Hypertension (%) 56.8 50.0
Dyslipidemia (%) 38.9 50.0
Diabetes (%) 11.1 16.1
Smoking History (%) Former (>1 year) 22.9 20.0
Current 5.7 16.7
Height (ins.) 69 (66, 73) 68.5 (65.5, 70)
Weight (lbs.) 200 (162, 230) 195 (146.5, 233)
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of prior myocardial infarction, severe valvulopathy, car-
diac mass, or infiltrative disorder. Cardiac parameters
were abstracted from available CMR reports. Blood sam-
ples were measured with a highly sensitive assay using an
automated platform (Cobas-e411 Troponin T hs, Roche
Diagnostics). Subsequent hospitalization for decompen-
sated heart failure, mechanical circulatory support, or
heart transplant were abstracted from the available elec-
tronic health record (EHR). Deaths were abstracted from
the EHR and the Social Security Death Index.
Results
Of 98 eligible patients, 74 had follow-up data available
(median follow-up 2.3 [interquartile range (IQR) 0.9,
4.3] years) (Table 1). Over the interval period, there
were 15 heart failure events (3 deaths, 13 heart failure
hospitalizations). In patients without LGE, there was a
trend toward an association between hs-cTnT and heart
failure outcomes (p = 0.07) (Figure). In patients with
LGE, there was a significant association between hs-
cTnT and heart failure outcomes (p = 0.048) (Figure 1).
Conclusions
In patients with non-ischemic cardiomyopathy, cardiac
troponin T levels measured with a highly sensitive assay
are associated with heart failure outcomes in the pre-
sence of late gadolinium enhancement. These findings
may support a strategy of combining LGE detection and
hs-cTnT levels to risk-stratify further patients with non-
ischemic cardiomyopathy.
Authors’ details
1Medicine, Baylor College of Medicine, Houston, TX, USA. 2Piedmont
Healthcare, Atlanta, GA, USA. 3Houston Methodist Hospital, Houston, TX,
USA. 4Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Published: 27 January 2016
doi:10.1186/1532-429X-18-S1-P121
Cite this article as: Yang et al.: Prognostic implications of myocardial
fibrosis and troponin levels measured by a highly sensitive assay in
non-ischemic cardiomyopathy. Journal of Cardiovascular Magnetic
Resonance 2016 18(Suppl 1):P121.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Table 1 Baseline characteristics, cardiac parameters derived from magnetic resonance imaging, and serum troponin
levels. (Continued)
Body surface area (m^2) 2.09 (1.85, 2.30) 2.05 (1.79, 2.28)
Systolic blood pressure (mm Hg) 117 (111,141) 117 (108, 133)
Diastolic blood pressure (mm Hg) 76 (65, 81) 71 (64, 82)
Heart rate (bpm) 80 (70, 86) 74 (64, 86)
Left atrial volume (mL) 109 (87, 165) 122 (87, 179)
Left ventricular ejection fraction (%) 37 (27, 45) 35 (27, 46)
Left ventricular end-diastolic volume (mL) 200 (156, 238) 214 (170, 264)
Left ventricular end-systolic volume (mL) 127 (80, 155) 133 (88, 185)
Left ventricular stroke volume (mL) 68 (53, 79) 74 (63, 91)
Left ventricular muscle mass (gm) 127.95 (128.00, 201.40) 177.00 (132.70, 223.00)
Left ventricular fibrosis percentage (%)† 0.00 (0.00, 0.00) 3.00 (2.00, 7.00)
Troponin T (ng/L) 8.0 (4.0, 21.0) 14.0 (7.0, 21.0)
*All values are proportions or median (interquartile range).
†p <0.05 (by Chi-squared or Fisher exact for categorical variables as appropriate; Wilcoxon rank sum test for continuous variables).
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Figure 1 Kaplan-Meier event-free survival estimates from heart failure events in non-ischemic cardiomyopathy patients in the absence
(top panel) and presence (bottom panel) of myocardial fibrosis on delayed enhancement imaging. Each group of patients were sub-
divided by tertiles of cardiac troponin T measured with a highly sensitive assay (hs-cTnT).
Yang et al. Journal of Cardiovascular Magnetic
Resonance 2016, 18(Suppl 1):P121
http://www.jcmr-online.com/content/18/S1/P121
Page 3 of 3
